Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of GPC2 Chimeric Antigen Receptor T (GPC2-CAR T) Cells for Relapsed or Refractory Medulloblastoma in Children and Young Adults

NCT07087002 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT07087002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07087002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of GPC2 Chimeric Antigen Receptor T (GPC2-CAR T) Cells for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Recruiting
Start date
August 28, 2025
Completion date
August 31, 2027
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atypical teratoid/rhabdoid tumor (atrt) of the cns, central nervous system embryonal tumor, childhood, cns neuroblastoma, embryonal tumor with multilayered rosettes (etmr), foxr2-activated, medulloblastoma, pediatric brain tumor, pineoblastoma, recurrent medulloblastoma, refractory medulloblastoma